CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	101.21	53.16	37.31	68.43	26.9
Revenue Growth (YoY)	90.38%	42.48%	-45.47%	154.36%	-54.79%
Gross Profit	101.21	53.16	37.31	68.43	26.9
Selling, General & Admin	30.02	42.85	39.16	36.03	36.77
Research & Development	77.68	111.65	114.19	112.94	131.62
Operating Expenses	107.7	154.5	153.35	148.97	168.38
Operating Income	-6.48	-101.34	-116.04	-80.54	-141.48
Other Expense / Income	-9.81	-2.02	-0.17	-1.81	-8.23
Pretax Income	3.32	-99.32	-115.87	-78.73	-133.25
Income Tax	3.89	0	0	-13.91	-0.43
Net Income	-0.57	-99.32	-115.87	-64.82	-132.83
Shares Outstanding (Basic)	74	66	64	46	45
Shares Outstanding (Diluted)	74	66	64	46	45
Shares Change	12.27%	2.48%	39.01%	1.79%	8.81%
EPS (Basic)	-0.01	-1.51	-1.81	-1.40	-2.93
EPS (Diluted)	-0.01	-1.51	-1.81	-1.40	-2.93
Free Cash Flow	-56.88	-112.53	-120.64	2.95	-143.98
Free Cash Flow Per Share	-0.77	-1.71	-1.88	0.06	-3.18
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-6.41%	-190.61%	-311.00%	-117.70%	-525.92%
Profit Margin	-0.56%	-186.82%	-310.54%	-94.73%	-493.74%
Free Cash Flow Margin	-56.19%	-211.67%	-323.33%	4.31%	-535.19%
Effective Tax Rate	117.12%	-	-	-	-
EBITDA	9.23	-93.46	-110.03	-73.27	-127.98
EBITDA Margin	9.12%	-175.80%	-294.89%	-107.08%	-475.71%
Depreciation & Amortization	5.9	5.86	5.84	5.46	5.28
EBIT	3.32	-99.32	-115.87	-78.73	-133.25
EBIT Margin	3.28%	-186.82%	-310.54%	-115.06%	-495.32%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).